{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "38820374", "DateCompleted": {"Year": "2024", "Month": "06", "Day": "27"}, "DateRevised": {"Year": "2024", "Month": "06", "Day": "27"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2024", "Month": "06", "Day": "03"}], "ELocationID": ["10.1097/JCP.0000000000001876"], "Journal": {"ISSN": "1533-712X", "JournalIssue": {"Volume": "44", "Issue": "4", "PubDate": {"MedlineDate": "2024 Jul-Aug 01"}}, "Title": "Journal of clinical psychopharmacology", "ISOAbbreviation": "J Clin Psychopharmacol"}, "ArticleTitle": "Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study.", "Pagination": {"StartPage": "369", "EndPage": "377", "MedlinePgn": "369-377"}, "Abstract": {"AbstractText": ["New sleep-inducing drugs (eg, ramelteon, suvorexant, and lemborexant) have been shown to prevent delirium in high-risk groups. However, no single study has simultaneously evaluated the delirium-preventing effects of all novel sleep-inducing drugs in hospitalized patients. Therefore, this study aimed to clarify the relationship between sleep-inducing drugs and delirium prevention in patients hospitalized in general medical-surgical settings for nonpsychiatric conditions who underwent liaison interventions for insomnia.", "This retrospective cohort study included patients treated in general medical-surgical settings for nonpsychiatric conditions with consultation-liaison psychiatry consult for insomnia. Delirium was diagnosed by fully certified psychiatrists using the Diagnostic and Statistical Manual of Mental Disorders 5 th edition. The following items were retrospectively examined from medical records as factors related to delirium development: type of sleep-inducing drugs, age, sex, and delirium risk factors. The risk factors of delirium development were calculated using adjusted odds ratios (aORs) via multivariate logistic regression analysis.", "Among the 710 patients analyzed, 257 (36.2%) developed delirium. Suvorexant (aOR, 0.61; 95% confidence interval [CI], 0.40-0.94; P = 0.02) and lemborexant (aOR, 0.23; 95% CI, 0.14-0.39; P < 0.0001) significantly reduced the risk of developing delirium. Benzodiazepines (aOR, 1.90; 95% CI, 1.15-3.13; P = 0.01) significantly increased this risk. Ramelteon (aOR, 1.30; 95% CI, 0.84-2.01; P = 0.24) and Z-drugs (aOR, 1.27; 95% CI, 0.81-1.98; P = 0.30) were not significantly associated with delirium development.", "The use of suvorexant and lemborexant may prevent delirium in patients with a wide range of medical conditions."], "CopyrightInformation": "Copyright \u00a9 2024 Wolters Kluwer Health, Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "From the Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan."}], "LastName": "Henmi", "ForeName": "Ryuji", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "From the Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan."}], "LastName": "Nakamura", "ForeName": "Tomoyuki", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Mashimoto", "ForeName": "Masaya", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Takase", "ForeName": "Fumitake", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "From the Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan."}], "LastName": "Ozone", "ForeName": "Motohiro", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Clin Psychopharmacol", "NlmUniqueID": "8109496", "ISSNLinking": "0271-0749"}, "ChemicalList": [{"RegistryNumber": "081L192FO9", "NameOfSubstance": "suvorexant"}, {"RegistryNumber": "901AS54I69", "NameOfSubstance": "ramelteon"}, {"RegistryNumber": "0", "NameOfSubstance": "Indenes"}, {"RegistryNumber": "0", "NameOfSubstance": "Triazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Azepines"}, {"RegistryNumber": "0K5743G68X", "NameOfSubstance": "lemborexant"}, {"RegistryNumber": "0", "NameOfSubstance": "Sleep Aids, Pharmaceutical"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["prevention & control", "drug therapy"], "DescriptorName": "Delirium"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Retrospective Studies"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Indenes"}, {"QualifierName": ["therapeutic use", "adverse effects"], "DescriptorName": "Triazoles"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["therapeutic use", "adverse effects"], "DescriptorName": "Azepines"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["therapeutic use", "adverse effects"], "DescriptorName": "Sleep Aids, Pharmaceutical"}, {"QualifierName": ["statistics & numerical data"], "DescriptorName": "Hospitalization"}, {"QualifierName": [], "DescriptorName": "Aged, 80 and over"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Sleep Initiation and Maintenance Disorders"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Risk Factors"}, {"QualifierName": [], "DescriptorName": "Pyridines"}, {"QualifierName": [], "DescriptorName": "Pyrimidines"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet . 2014;38:911\u2013922."}, {"Citation": "Salluh JI, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ . 2015;350:h2538."}, {"Citation": "Hosie A, Davidson PM, Agar M, et al. Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: a systematic review. Palliat Med . 2013;27:486\u2013498."}, {"Citation": "Pendlebury ST, Lovett NG, Smith SC, et al. Observational, longitudinal study of delirium in consecutive unselected acute medical admissions: age-specific rates and associated factors, mortality and re-admission. BMJ Open . 2015;5:e007808."}, {"Citation": "van den Boogaard M, Schoonhoven L, van der Hoeven JG, et al. Incidence and short-term consequences of delirium in critically ill patients: a prospective observational cohort study. Int J Nurs Stud . 2012;49:775\u2013783."}, {"Citation": "Ouimet S, Riker R, Bergeron N, et al. Subsyndromal delirium in the ICU: evidence for a disease spectrum. Intensive Care Med . 2007;33:1007\u20131013."}, {"Citation": "Pereira JV, Aung Thein MZ, Nitchingham A, et al. Delirium in older adults is associated with development of new dementia: a systematic review and meta-analysis. Int J Geriatr Psychiatry . 2021;36:993\u20131003."}, {"Citation": "Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA . 2004;291:1753\u20131762."}, {"Citation": "Anand A, Cheng M, Ibitoye T, et al. Positive scores on the 4AT delirium assessment tool at hospital admission are linked to mortality, length of stay and home time: two-centre study of 82,770 emergency admissions. Age Ageing . 2022;51:afac05."}, {"Citation": "Weinrebe W, Johannsdottir E, Karaman M, et al. What does delirium cost? An economic evaluation of hyperactive delirium. Z Gerontol Geriatr . 2016;49:52\u201358."}, {"Citation": "Leslie DL, Marcantonio ER, Zhang Y, et al. One-year health care costs associated with delirium in the elderly population. Arch Intern Med . 2008;168:27\u201332."}, {"Citation": "Hall RJ, Watne LO, Cunningham E, et al. CSF biomarkers in delirium: a systematic review. Int J Geriatr Psychiatry . 2018;33:1479\u20131500."}, {"Citation": "Meagher DJ, Moran M, Raju B, et al. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry . 2007;190:135\u2013141."}, {"Citation": "Meissner HH, Riemer A, Santiago SM, et al. Failure of physician documentation of sleep complaints in hospitalized patients. West J Med . 1998;169:146\u2013149."}, {"Citation": "Dobing S, Frolova N, McAlister F, et al. Sleep quality and factors influencing self-reported sleep duration and quality in the general internal medicine inpatient population. PloS One . 2016;11:e0156735."}, {"Citation": "Devlin JW, Skrobik Y, G\u00e9linas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med . 2018;46:e825\u2013e873."}, {"Citation": "Kakar E, Priester M, Wessels P, et al. Sleep assessment in critically ill adults: a systematic review and meta-analysis. J Crit Care . 2022;71:154102."}, {"Citation": "Doi Y, Minowa M, Okawa M, et al. Prevalence of sleep disturbance and hypnotic medication use in relation to sociodemographic factors in the general Japanese adult population. J Epidemiol . 2000;10:79\u201386."}, {"Citation": "Fok M, Stewart R, Besset A, et al. Incidence and persistence of sleep complaints in a community older population. Int J Geriatr Psychiatry . 2010;25:37\u201345."}, {"Citation": "Czeisler CA, Dumont M, Duffy JF, et al. Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet . 1992;340:933\u2013936."}, {"Citation": "Siddiqi N, Harrison JK, Clegg A, et al. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev . 2016;3:CD005563."}, {"Citation": "Wu YC, Tseng PT, Tu YK, et al. Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: a network meta-analysis. JAMA Psychiatry . 2019;76:526\u2013535."}, {"Citation": "Ogawa A, Okumura Y, Fujisawa D, et al. Quality of care in hospitalized cancer patients before and after implementation of a systematic prevention program for delirium: the DELTA exploratory trial. Support Care Cancer . 2019;27:557\u2013565."}, {"Citation": "Nagamine T. Long-term preoperative use of zolpidem is associated with postoperative delirium in elderly patients undergoing hip surgery. Psychogeriatrics . 2021;21:689\u2013690."}, {"Citation": "Mangusan RF, Hooper V, Denslow SA, et al. Outcomes associated with postoperative delirium after cardiac surgery. Am J Crit Care . 2015;24:156\u2013163."}, {"Citation": "Xu S, Cui Y, Shen J, et al. Suvorexant for the prevention of delirium: a meta-analysis. Medicine (Baltimore) . 2020;99:e21043."}, {"Citation": "Adams AD, Pepin MJ, Brown JN. The role of suvorexant in the prevention of delirium during acute hospitalization: a systematic review. J Crit Care . 2020;59:1\u20135."}, {"Citation": "Tanifuji T, Otsuka I, Okazaki S, et al. Preventive effects of preoperative ramelteon on postoperative delirium in Asian elderly population: a randomized, double-blind, placebo-controlled trial, and a systematic review and meta-analysis. Asian J Psychiatr . 2022;78:103282."}, {"Citation": "Zhang Q, Gao F, Zhang S, et al. Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Sleep Breath . 2019;23:1059\u20131070."}, {"Citation": "Hatta K, Kishi Y, Wada K, et al. Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. J Clin Psychiatry . 2017;78:e970\u2013e979."}, {"Citation": "Azuma K, Takaesu Y, Soeda H, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg . 2018;5:362\u2013368."}, {"Citation": "Masuyama T, Sanui M, Yoshida N, et al. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics . 2018;18:209\u2013215."}, {"Citation": "Izuhara M, Izuhara HK, Tsuchie K, et al. Real-world preventive effects of suvorexant in intensive care delirium: a retrospective cohort study. J Clin Psychiatry . 2020;81:20m13362."}, {"Citation": "Tamura K, Maruyama T, Sakurai S. Preventive effect of suvorexant for postoperative delirium after coronary artery bypass grafting. Ann Thorac Cardiovasc Surg . 2019;25:26\u201331."}, {"Citation": "Tian Y, Qin Z, Han Y. Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis. Psychogeriatrics . 2022;22:259\u2013268."}, {"Citation": "Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry . 2014;71:397\u2013403."}, {"Citation": "Hatta K, Kishi Y, Wada K, et al. Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors. J Clin Psychiatry . 2019;81:19m12865."}, {"Citation": "Nishikimi M, Numaguchi A, Takahashi K, et al. Effect of administration of ramelteon, a melatonin receptor agonist, on the duration of stay in the ICU: a single-center randomized placebo-controlled trial. Crit Care Med . 2018;46:1099\u20131105."}, {"Citation": "Hokuto D, Nomi T, Yoshikawa T, et al. Preventative effects of ramelteon against postoperative delirium after elective liver resection. PloS One . 2020;15:e0241673."}, {"Citation": "Wang CM, Zhou LY. Melatonin and melatonergic agents for the prevention of postoperative delirium: a meta-analysis of randomized placebo-controlled trials. Asian J Surg . 2022;45:27\u201332."}, {"Citation": "Han Y, Tian Y, Wu J, et al. Melatonin and its analogs for prevention of post-cardiac surgery delirium: a systematic review and meta-analysis. Front Cardiovasc Med . 2022;9:888211."}, {"Citation": "Oh ES, Leoutsakos JM, Rosenberg PB, et al. Effects of ramelteon on the prevention of postoperative delirium in older patients undergoing orthopedic surgery: the RECOVER randomized controlled trial. Am J Geriatr Psychiatry . 2021;29:90\u2013100."}, {"Citation": "Terada T, Hirayama T, Sadahiro R, et al. Pilot study of Lemborexant for insomnia in cancer patients with delirium. J Palliat Med . 2022;25:797\u2013801."}, {"Citation": "Matsuoka A, Tobita S, Sogawa R, et al. Evaluation of suvorexant and lemborexant for the prevention of delirium in adult critically ill patients at an advanced critical care center: a single-center, retrospective, observational study. J Clin Psychiatry . 2022;84:22m14471."}, {"Citation": "American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). 2013."}, {"Citation": "Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry . 1999;156:1\u201320."}, {"Citation": "Green SB. How many subjects does it take to do a regression analysis. Multivariate Behav Res . 1991;26:499\u2013510."}, {"Citation": "Ormseth CH, LaHue SC, Oldham MA, et al. Predisposing and precipitating factors associated with delirium: a systematic review. JAMA Netw Open . 2023;6:e2249950."}, {"Citation": "Hori Y, Mihashi M. Relationship between delirium development and its causative factors in the intensive care unit after cardiac surgery. Yonago Acta Med . 2023;66:214\u2013222."}, {"Citation": "Kuzuhara S. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. J Neurol . 2001;248(suppl 3):III28\u2013III31."}, {"Citation": "Cant\u00fa TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med . 1991;114:1027\u20131034."}, {"Citation": "Yu CL, Carvalho AF, Thompson T, et al. Ramelteon for delirium prevention in hospitalized patients: an updated meta-analysis and trial sequential analysis of randomized controlled trials. J Pineal Res . 2023;74:e12857."}, {"Citation": "Beuckmann CT, Suzuki M, Ueno T, et al. In vitro and in Silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther . 2017;362:287\u2013295."}, {"Citation": "Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron . 2003;38:715\u2013730."}, {"Citation": "Sharpley AL, Attenburrow ME, Hafizi S, et al. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry . 2005;66:450\u2013454."}, {"Citation": "Gim\u00e9nez S, Clos S, Romero S, et al. Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacology (Berl) . 2007;190:507\u2013516."}, {"Citation": "Monti JM, Torterolo P, Pandi-Perumal SR. The effects of benzodiazepine and nonbenzodiazepine agents, ramelteon, low-dose doxepin, suvorexant, and selective serotonin 5-HT2A receptor antagonists and inverse agonists on sleep and wakefulness. Clin Med Insights Ther . 2016;8:29\u201336."}, {"Citation": "Moline M, Zammit G, Cheng JY, et al. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin Sleep Med . 2021;17:1167\u20131174."}, {"Citation": "Trompeo AC, Vidi Y, Locane MD, et al. Sleep disturbances in the critically ill patients: role of delirium and sedative agents. Minerva Anestesiol . 2011;77:604\u2013612."}, {"Citation": "Mullington JM, Simpson NS, Meier-Ewert HK, et al. Sleep loss and inflammation. Best Pract Res Clin Endocrinol Metab . 2010;24:775\u2013784."}, {"Citation": "Pollm\u00e4cher T, Schuld A, Kraus T, et al. Experimental immunomodulation, sleep, and sleepiness in humans. Ann N Y Acad Sci . 2000;917:488\u2013499."}, {"Citation": "Uemura N, McCrea J, Sun H, et al. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol . 2015;55:1093\u20131100."}, {"Citation": "Snyder E, Ma J, Svetnik V, et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med . 2016;19:93\u2013100."}, {"Citation": "Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology . 2012;79:2265\u20132274."}, {"Citation": "Dubey AK, Handu SS, Mediratta PK. Suvorexant: the first orexin receptor antagonist to treat insomnia. J Pharmacol Pharmacother . 2015;6:118\u2013121."}, {"Citation": "Gim\u00e9nez S, Romero S, Ma\u00f1anas MA, et al. Waking and sleep electroencephalogram variables as human sleep homeostatic process biomarkers after drug administration. Neuropsychobiology . 2011;63:252\u2013260."}, {"Citation": "Katshu MZUH, Sarkar S, Nizamie SH. Effect of olanzapine on clinical and polysomnography profiles in patients with schizophrenia. Schizophr Res Treatment . 2018;2018:3968015."}, {"Citation": "Mistraletti G, Sabbatini G, Taverna M, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res . 2010;48:142\u2013147."}, {"Citation": "Marcantonio ER, Juarez G, Goldman L, et al. The relationship of postoperative delirium with psychoactive medications. JAMA . 1994;272:1518\u20131522."}, {"Citation": "Yajima S, Nakanishi Y, Matsumoto S, et al. The Mini-cog: a simple screening tool for cognitive impairment useful in predicting the risk of delirium after major urological cancer surgery. Geriatr Gerontol Int . 2022;22:319\u2013324."}, {"Citation": "Declerck AC, Ruwe F, O'Hanlon JF, et al. Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia. Psychopharmacology (Berl) . 1992;106:497\u2013501."}, {"Citation": "Morairty SR, Hedley L, Flores J, et al. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep . 2008;31:34\u201344."}, {"Citation": "Bettica P, Squassante L, Groeger JA, et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology . 2012;37:1224\u20131233."}, {"Citation": "Uemura SI, Imanishi A, Terui Y, et al. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: a randomized double-blind study. Neuropsychopharmacol Rep . 2022;42:288\u2013298."}, {"Citation": "Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med . 2008;4:229\u2013234."}, {"Citation": "Bamgbade OA, Tai-Osagbemi J, Bamgbade DO, et al. Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. J Clin Sleep Med . 2022;18:1565\u20131571."}, {"Citation": "Anand S, Tong H, Besag FMC, et al. Safety, tolerability and efficacy of drugs for treating Behavioural insomnia in children with attention-deficit/hyperactivity disorder: a systematic review with methodological quality assessment. Paediatr Drugs . 2017;19:235\u2013250."}, {"Citation": "Kurisu K, Miyabe D, Furukawa Y, et al. Association between polypharmacy and the persistence of delirium: a retrospective cohort study. Biopsychosoc Med . 2020;14:25."}, {"Citation": "Bj\u00f6rkelund KB, Hommel A, Thorngren KG, et al. Reducing delirium in elderly patients with hip fracture: a multi-factorial intervention study. Acta Anaesthesiol Scand . 2010;54:678\u2013688."}, {"Citation": "O'Mahony R, Murthy L, Akunne A, et al. Synopsis of the National Institute for health and clinical excellence guideline for prevention of delirium. Ann Intern Med . 2011;154:746\u2013751."}, {"Citation": "Swart LM, van der Zanden V, Spies PE, et al. The comparative risk of delirium with different opioids: a systematic review. Drugs Aging . 2017;34:437\u2013443."}, {"Citation": "Mahanna-Gabrielli E, Miano TA, Augoustides JG, et al. Does the melatonin receptor 1B gene polymorphism have a role in postoperative delirium? PloS One . 2018;13:e0207941."}], "ReferenceList": []}], "History": [{"Year": "2024", "Month": "6", "Day": "27", "Hour": "18", "Minute": "41"}, {"Year": "2024", "Month": "5", "Day": "31", "Hour": "18", "Minute": "42"}, {"Year": "2024", "Month": "5", "Day": "31", "Hour": "15", "Minute": "24"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38820374", "10.1097/JCP.0000000000001876", "00004714-990000000-00258"]}}], "PubmedBookArticle": []}